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Abstract: The ability of S-adenosyl-L-homocysteine (AdoHcy) to inhibit 
biologic transmethylation reactions in vitro has led us to explore the possibility 
of pharmacologically manipulating AdoHcy levels in vivo and examining the 
consequences of these alterations on the transmethylation of some biogenic 
amines. Swiss-Webster mice were injected intraperitoneally with different 
doses of adenosine (Ado) and D,L-homocysteine thiolactone (Hcy) and were 
killed at various times thereafter. S-Adenosyl-L-methionine (AdoMet) and 
AdoHcy concentrations were determined by using a modified isotope 
dilution-ion exchange chromatography-high pressure liquid chromatography 
technique sensitive to less than 10 pmol. Increasing doses of Ado + Hcy 
(50- lo00 mg/kg of each) produced a dose-related increase in blood, liver, and 
brain AdoHcy levels. At a dose level of 200 mg/kg Ado + Hcy, AdoHcy levels 
were markedly elevated, with minimal concomitant perturbations of AdoMet. 
This elevation was maximal 40 min after giving Ado + Hcy, returning to con- 
trol values within 6 h. Ado + Hcy treatment resulted in decreased activities of 
catechol-0-methyltransferase, histamine-N-methyltransferase, and AdoHcy 
hydrolase in vitro. The cerebral catabolism of intraventricularly administered 
[3H]histamine (HA) was decreased in a dose-related manner by Ado + Hcy 
treatment as evidenced by higher amounts of nonutilized [3H]HA in brain, 
concurrent decreases in [3H]methylhistamine formation, and decreases in the 
transmethylation conversion index. Steady state levels of HA also showed 
dose-related increases after Ado + Hcy treatment. It is concluded that injec- 
tions of Ado + Hcy can markedly elevate AdoHcy levels in vivo, which can, in 
turn,  decrease the  rate  of  transmethylation reactions. Key Words: 
Transmethylation-Biogenic amineS-AdenosylhomocysteineS-Adenosyl- 
methionine-HPLC. Schatz R. A. e t  al. Decreased transmethylation of bio- 
genic amines after in vivo eleyation of brain S-adenosyl-L-homocysteine. 
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It is well established that S-adenosyl-L-homo- 
cysteine (AdoHcy) is a potent inhibitor, in vifro, of 
transmethylation reactions utilizing S-adenosyl-L- 
methionine (AdoMet) as the methyl donor. These 
enzymes include: tyramine-N-methyltransferase 
(EC 2.1.1.2’1) (Mann and Mudd, 1%3), catechol- 
0-methyltransferase (EC 2.1.1.6) (COMT), phenyl- 
ethanolamine-N-methyltransferase (EC 2.1.1.28) 
and acetylserotonin methyltransferase (EC 2.1.1.4) 
(Deguchi and Barchas, 1971), histamine-N-methyl- 
transferase (HMT) (EC 2.1.1.8) (Zappia et al., 1%9; 
Baudry et al., 1973; Borchardt et al., 1978), histone 
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methyltransferase (EC 2.1.1.42) (Hoffman et al., 
1979), phosphatidylethanolamine methyltransferase 
(EC 2.1.1.17) (Chung and Law, 1964; Schneider and 
Vance, 1979), tRNA methyltransferase (EC 
2.1.1.29-36) (Leboy et al., 1978; Salas and Sel- 
linger, 1978), mRNA methyltransferase (Borchardt 
and Pugh, 1979), DNA methyltransferase (EC 
2.1.1.37) (Cox et al., 1977), and protein methyl- 
transferases 1-111 (EC 2.1.1.23, 2.1.1.24, 2.1.1.43) 
(Kim, 1974). In addition, AdoHcy inhibits N5-meth- 
yltetrahydrofolate-homocysteine methyltransferase 
(EC 2.1.1.13) (Burke et al., 1971) and spermine 
synthase (EC 2.5.1.16) (Hibasami and Pegg, 1978). 
Further interest in AdoHcy and the enzyme respon- 
sible for its hydrolysis, AdoHcy hydrolase (EC 
3.3.1.1) (Schatz et al., 1979), has been spurred by 
the finding that some synthetic AdoHcy analogues 
prevent the oncogenic transformation of chick em- 
bryo fibroblasts infected with Rous sarcoma virus 
or Gross murine leukemia virus (Robert-Gero et al., 
1975; Legraverend et al., 1977; Pierre et al., 1977; 
Chiang et al., 1978). Furthermore, elevated AdoHcy 
levels have been implicated in adenosine toxicity 
seen in T and B lymphoma cells (Kredich and 
Martin, 1977; Palella et al., 1980). 
Recent pharmacologic studies have shown that 
AdoHcy administration increases the urinary 
excretion of dopamine (DA) and norepinephrine 
(NE) without concurrent alterations in urinary 
levels of 3-O-methyldopamine (MD) or normeta- 
nephrine (MN) (Bidard et al., 1979). In brain, 
AdoHcy administration increases NE synthesis 
and decreases serotonin (5-HT) synthesis and 
levels without altering DA metabolism (Fonlupt et 
al., 1979). After intracisternal [14C]DA or [3H]NE, 
brain levels of [14C]MD and [3H]NM were (unex- 
pectedly) elevated in AdoHcy-treated rats (Bidard 
et al., 1979). Previously, Baudry et al. (1973) have 
shown that AdoHcy treatment had no effect on 
the catabolism of intracisternally administered 
[3H]histamine (HA) in rat brain. Definitive inter- 
pretation of the findings of the aforementioned 
studies, however, is hampered by the fact that no 
attempt was made to correlate the biochemical 
changes with tissue levels of AdoHcy and AdoMet. 
Recently, it has also been shown that the admin- 
istration of the AdoHcy hydrolase inhibitor, 3- 
deazaadenosine (3-deazaAdo) to rats increased tis- 
sue AdoMet and AdoHcy levels and decreased liver 
cteatinine levels, the urinary excretion of 3- 
methoxy-4hydroxymandelic acid (VMA), and he- 
patic phospholipid methylation (Chiang and Can- 
toni, 1979; Chiang et al., 1980). 
It was the objective of our studies to find an ef- 
fective means of elevating brain AdoHcy levels, 
without severely perturbing those of AdoMet, and 
to determine the consequence of such high AdoHcy 
levels on several transmethylation reactions. 
MATERIALS AND METHODS 
An ima 1s 
Adult male Swiss-Webster mice (24-32 g) were from 
Charles River Laboratories (Portage, Michigan). The 
mice were fasted overnight prior to the experimental pro- 
cedures, which were conducted between 8:OO and 11:OO 
a.m. to minimize possible diurnal variation. 
Drug Treatment and Tissue Collection 
Mice were injected intraperitoneally with different 
doses of S-adenosyl-L-homocysteine (AdoHcy) or of an 
equimolar mixture of adenosine (Ado) plus D,L-homo- 
cysteine thiolactone (Hcy) (20 mVkg) suspended in saline 
containing Tween 80 (2.5%). At various times after drug 
administration, the mice were decapitated and the heads 
dropped into liquid nitrogen, after which the brains were 
removed and refrozen in liquid nitrogen. Trunk blood was 
collected directly into liquid nitrogen and livers were 
rapidly excised after blood collection and frozen, as 
above. A11 tissues were stored at -80°C until time of 
assay. In experiments where in vitro enzyme activity de- 
terminations were made, brains and livers were rapidly 
excised and placed into ice-cold, tared beakers containing 
the respective buffers required for assay. 
Determination of AdoMet and AdoHcy Levels 
AdoHcy and AdoMet disulfate di-p-toluenesulfonate 
were generously donated by Dr. Giorgio Stramentinoli 
(BioResearch Laboratories, Liscate, Italy). Amberlite 
CG-50 was from Accurate Chemical (Hicksville, New 
York), and Dowex 50W-X8 (200-400 mesh), from 
BioRad (Richmond, California). [MethyLt4C]AdoMet 
(specific activity 57 mCi/mmol) and [8-"C]Ado (specific 
activity 54 mCi/mmol) were from New England Nuclear 
(Boston, Massachusetts). Radioactive AdoHcy (8-14C) 
was prepared from L-HCY and [8-"C]Ado as previously 
described (Schatz e t  al., 1977a). The AdoHcy was 
purified with a Waters high pressure liquid chromatog- 
raphy (HPLC) instrument on a pBondapak C18 column. 
AdoHcy was eluted with 0.04 M-ammonium formate (10% 
methanol) (2 mUmin), after which the sample was lyophi- 
lized, dissolved in water, and stored in small aliquots at 
-80°C until use. AdoMet and AdoHcy levels were deter- 
mined by using a modified isotope-dilution method 
(Schatz and Sellinger, 1975~;  Schatz et al., 19773). To 
weighed, frozen tissues were added [14C]AdoMet and 
AdoHcy (1 -7 x 1Oj d.p.m./pmol) in a sufficient quantity 
to dilute the normal, endogenous tissue concentrations by 
about 40%. The tissues were homogenized in 5 ml ice- 
cold 0.4 M-perchloric acid and centrifuged (10,OOO g for 10 
min). The supernatants were adjusted to pH 5.5-6 by 
stepwise addition of KOH (10 M, I M, 0.1 M )  in an ice 
bath, and the volume was adjusted to 8 ml with water. 
After centrifugation as above, the supernatant was di- 
vided into two 4-ml fractions. For AdoMet determination, 
4 ml of supernatant was applied to a Dowex-50 (Na+) 
column (0.7 X 3 cm) previously equilibrated with 0.1 
M-NaCI. The column was washed with 15 ml of 0.1 M- 
NaCl and 5 ml water, and AdoMet was eluted with 5 ml of 
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6 M-HCI. The HCI fraction was lyophilized and dissolved 
in 0.5 ml water, after which 25-50 pl was injected onto a 
pBondapak C-18 column. AdoMet was eluted with 0.04 
M-monobasic ammonium phosphate (1% methanol) (2 
mllmin). The AdoMet peak was collected and a 0.5-ml 
aliquot counted in 5 ml of ACS (a tissue solubilizer- 
scintillation mixture-Amersham-Searle, Arlington 
Heights, Illinois). Tissue concentrations of AdoMet were 
calculated by using the isotope-dilution equation (Wang 
and Willis, 1%5). 
For AdoHcy determination, the remaining 4 ml was 
applied to an Amberlite CG-50 (H+) column (0.7 x 3 cm) 
previously equilibrated with water. The column was 
washed with 15 ml of 0.03 M-ammonium hydroxide, and 
AdoHcy was eluted with 5 ml of 3 M-ammonium hydrox- 
ide. The AdoHcy fraction was lyophilized and dissolved 
in 0.5 ml water, after which 100 pI was injected onto a 
pBondapak C-18 column. AdoHcy was eluted with 0.04 
M-monobasic ammonium phosphate (7.5% methanol) (2 
mllmin). The rest of the experimental procedure was 
identical to that used for determination of AdoMet. This 
assay technique is capable of detecting as little as 10 pmol 
AdoMet or AdoHcy. 
In Vivo Histamine Methylation and Endogenous 
Histamine Levels 
Histamine dihydrochloride H ~ L S  from Sigma (St. Louis, 
Missouri); 3-methylhistamine and 3-methylimidazole- 
acetic acid were from Calbiochem (LaJolla, California); 
silica gel thin-layer chromatography (TLC) plates from 
New England Nuclear (Boston, Massachusetts) or EM 
Laboratories (Elmsford, New York); and [2,S3H]hista- 
mine dihydrochloride (specific activity 7.7 Cilmmol) from 
Amersham-Searle (Arlington Heights, Illinois). For intra- 
ventricular (i.vt.) histamine injections, the mice were 
lightly anesthetized with ether, a small piece of scalp re- 
moved for ease in identification of the injection site, and 
[3H]histamine was injected into the lateral cerebral ven- 
tricle in 10 pI of artificial cerebrospinal fluid (Merlis solu- 
tion) 5 min prior to death, which occurred following im- 
mersion of the whole animal (head first) into liquid nitro- 
gen. After overnight storage at -2O"C, whole brains were 
rapidly removed and immediately immersed in liquid ni- 
trogen, and then stored at -80°C. The determinations of 
[3H]histamine (HA), [SH]methylhistamine (MeHA), and 
[3H]methylimidazoleacetic acid (MeIAA) were as de- 
scribed by Schatz et al. (1978). Steady state histamine 
levels were measured by the single isotope procedure of 
Kobayashi and Maudsley (1972) as modified by Schatz et 
al. (1978). 
Determination of AdoHcy Hydrolase, HMT, 
and COMT 
Tissues were homogenized in 10 volumes (wh) ice-cold 
0.32 M-Sucrose. In some cases, homogenates were 
dialyzed overnight against three changes of 0.005 M- 
potassium phosphate buffer (pH 7.4). AdoHcy hydrolase 
was measured in the hydrolytic direction by HPLC on a 
pBondapak column according to Schatz,et al. (1977a), the 
only exception being the use of 0.04 M-monobasic am- 
monium phosphate (10% methanol) for the separation of 
AdoHcy and its catabolites. The assays of HMT and 
COMT were as described by Schatz and Sellinger (1975b) 
and Porcher and Heller (1972), respectively. Protein was 
determined according to Lowry et al. (1951). 
RESULTS 
AdoMet and AdoHcy Levels After AdoHcy 
or Ado + Hcy 
In preliminary studies, intraperitoneal injections 
of AdoHcy ( 1  g/kg) slightly increased cerebral 
AdoHcy (29%) and had no significant effect on he- 
patic AdoHcy levels (Table 1). Co-administration of 
Ado and Hcy (Ado + Hcy) (1  g/kg of each), how- 
ever, markedly elevated AdoHcy levels in both 
brain (970%) and liver (3200%) (Table 1). As co- 
administration of Ado + Hcy was capable of pro- 
ducing such large perturbations in AdoHcy levels 
(compared with AdoHcy), the balance of our inves- 
tigation was directed toward determining the 
biochemical consequences of administering Ado + 
Hcy. In brain, increasing doses of Ado + Hcy 
resulted in dose-related increases in AdoHcy, 
reaching maximal levels (1000%) at 1 glkg (Fig. 
1). Cerebral AdoMet levels, however, were not 
significantly altered by doses of Ado + Hcy of 
up to 500 mg/kg (Fig. 1). Administration of increas- 
ing doses of Ado i Hcy resulted in concurrent, 
dose-related, increases in hepatic levels of both 
TABLE 1. Effect of AdoHcy and Ado + Hcy on mouse brain and liver AdoHcy levels 
Brain Liver 
Treatmenta nmoVg 2 S.E.M. (N) % Changeb p c  nmoUg 2 S.E.M. (N) % Changeb p c  
- - 31.23 c 2.57 (7) - - Vehicle 6.89 c 0.57 (7) 
AdoHcy 8.88 f O.% (7) +29 ~ 0 . 0 5  37.47 c 7.60 (6) +20 NS 
Ado + Hcy 73.82 f 3.27 (6) +970 <0.005 1031.0 2 152.70 (6) +3200 <0.005 
" Mice were injected intrapentoneally with salineflween 80 (20 mUkg), S-adenosyl-L-homocysteine (1 glkg), or 
a combination of adenosine + D,r-homocysteine thiolactone (1 gkg of each) 90 min prior to killing. 
% Change values are compared with vehicle-treated animals. 
P values were determined by Student's ?-test (two-tailed); P values greater than 0.05 were considered not 
significant (NS). 
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FIG. 1. Effect of increasing doses of Ado + Hcy on mouse 
brain AdoHcy and AdoMet. Mice were injected intraperitone- 
ally with different doses of Ado + Hcy 90 min prior to death. 
AdoHcy and AdoMet levels are expressed as means ? S.E.M. 
in from four to seven mice. Open symbols denote significant 
differences compared with vehicle-treated controls at the 
0.05 level, using Student's t-test (two-tailed). 
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FIG. 2. Effect of increasing doses of Ado + Hcy on mouse 
liver AdoHcy and AdoMet. For details of drug treatment, ex- 
pression of results, and statistical analysis, see Fig. 1. 
AdoMet (650% at 500 mg/kg) and AdoHcy (2000% 
at 500 mg/kg) (Fig. 2 ) .  Blood levels of AdoMet were 
significantly increased (48%) only after 500 mg/kg of 
Ado + Hcy while AdoHcy levels progressively in- 
creased, reaching a maximal elevation (105%), also 
at a dose of 500 mdkg (Fig. 3). Use of 200 mg/kg of 
Ado + Hcy, the dose chosen in most subsequent 
experiments, resulted in a 600% increase in brain 
AdoHcy at 40 min and a return to control levels 
within 6 h (Fig. 4). As noted previously, brain 
AdoMet levels were unaltered by the Ado + Hcy 
treatment (Figs. 1 and 4). 
Effect of Ado + Hcy on AdoHcy Hydrolase, 
HMT, and COMT 
After Ado + Hcy administration, COMT and 
HMT activity were significantly decreased in 
/ 
\ 0)  10 J U blood 
1.5 T 
I i 2 50 5i 
m s / b  
FIG. 3. Effect of increasing doses of Ado + Hcy on mouse 
blood AdoHcy and AdoMet. For details of drug treatment, 
expression of results, and statistical analysis, see Fig. 1. 
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FIG. 4. Time course of altered mouse brain AdoHcy and 
AdoMet levels after Ado + Hcy. Ado + Hcy (200 mg/kg of 
each) were injected intraperitoneally into mice which were 
killed at the indicated times. For expression of results and 
statistical analysis, see Fig. 1. 
homogenates of brain and liver, the hepatic en- 
zymes being inhibited to a greater extent than those 
of brain (Fig. 5). Dialysis of brain and liver homog- 
enates from Ado + Hcy-treated mice effectively 
removed this inhibition in the case of HMT (Fig. 6). 
The presence of high levels of AdoHcy in 
Ado + Hcy-treated mice prevented an accurate 
determination of AdoHcy hydrolase activity in un- 
dialyzed tissue homogenates using HPLC. After 
dialysis, however, brain homogenates from 
Ado + Hcy-treated mice were found to have sig- 
nificantly decreased AdoHcy hydrolase activity, 
the maximal decrease occurring concurrently with 
the maximal elevation in cerebral AdoHcy content 
(40 min after Ado + Hcy) (Fig. 7). The activity of 
AdoHcy hydrolase, like the levels of AdoHcy (Fig. 
4), returned to control values within 6 h (Fig. 7). 
Effect of Ado + Hcy Administration on Brain 
Histamine Levels and 
r3H]Histamine Catabolism 
Since in vitro enzyme activity measurements are 
usually carried out at optimal substrate concentra- 
tions, using tissue preparations whose cellular in- 
tegrity has been drastically altered, we undertook to 
determine the effects of Ado + Hcy treatment on 
r3H]histamine catabolism in vivo, which, in brain, 
occurs primarily via transmethylation (Schwartz 
et al., 1971; Schatz et al., 1978). Brains of Ado + 
Hcy-treated mice contained 68% more E3H]HA 
at 50 mgkg and 215% more [3H]HA at 200 mgkg 
compared with vehicle-treated controls (Fig. 8). 
Concurrently, significant decreases (24% and 33%) 
in t3H]MeHA formation were noted. t3H]MeIAA 
levels were also slightly, although not significantly, 
decreased (Fig. 8). Further, the endogenous levels 
of brain histamine were increased in a dose-related 
fashion after Ado + Hcy (30% at 50 mglkg and 
66% at 200 mg/kg) (Table 2), while the MeHA con- 
version index, used as an estimate of the MeHA 
transmethylation flux (Schatz et al., 1978; 1981), 
was decreased by 42% at 50 mg/kg and by 66% 
at 200 mglkg of Ado + Hcy (Table 2). 
DISCUSSION 
There are a variety of techniques presently used 
to measure tissue levels of AdoMet and AdoHcy. 
AdoMet levels in rat or mouse liver range from as 
low as 37 nmoVg (Floridi et al., 1979) to as high as 
123 nmoYg (Lombardini and Talalay, 1973), while 
those of AdoHcy range from 10 nmoYg (Hoffman et 









I !1 0 LIVER BRAIN I BRAIN _oT FIG. 5. Effect of Ado + Hcy on mouse brain and liver histamine-N-methyltrans- ferase (HMT) and catechol-0-methyl- transferase (COMT). Enzyme activity val- ues are expressed as nmollmg proteinlh as means & S.E.M. in homogenates from six to seven animals. Mice were injected intraperitoneally with salinelTween 80 (20 ml/kg) (open bars) or Ado + Hcy (1 g/kg of each) (closed bars) 90 min prior to death. Stars indicate values significantly differ- ent from vehicle-treated controls at the 0.05 level, using the Student's t-test (two-tailed). 
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FIG. 7. Time course of altered mouse brain AdoHcy levels 
and AdoHcy hydrolase activity after Ado + Hcy. Mice were 
injected intraperitoneally with salinenween 80 (20 ml/kg) or 
Ado + Hcy (200 mg/kg of each) and killed at the times indi- 
cated. Values are expressed as means 2 S.E.M. in five to 
seven mice. Enzyme activity was determined in dialyzed tis- 
sue homogenates. Stars denote values significantly different 
from vehicle-treated controls (zero time) at the 0.05 level, 
using Student's t-test (two-tailed). 
i 
FIG. 6. Effect of dialysis on the inhibition 
of mouse brain and liver histamine#- 
methyltransferase (HMT) by Ado + Hcy. 
For drug treatment, expression of results, 
and statistical analysis, see Fig. 5. 
al., 1979) to 60 nmoUg (Salvatore et al., 1971; Floridi 
et al., 1979). Brain levels of both AdoMet (15-72 
nmoYg) (Salvatore et al., 1971; Taylor and Randall, 
1975) and AdoHcy (2.5-72 nmoYg) (Eloranta, 1977; 
Schatz et al., 19776) are generally lower than those 
of liver. AdoMet levels in human blood range from 
15 to 50 nmoUml (Illiano et al., 1971; Salvatore et 
al . ,  1971); and one investigation reports blood 
AdoHcy levels to be 32 nmoyml (Salvatore et al., 
1971). AdoMet and AdoHcy tissue levels reported 
herein (Table 1 ;  Figs. 1-3) were determined by 
B 3H- HA 
0 'H- MeHA 
SALINE 50MG/KG ZWMG/KG 
FIG. 8. Effect of Ado + Hcy on ['Hjhistamine catabolism in 
mouse brain. Mice were injected intraperitoneally with 
salinelTween 80 (20 ml/kg) or Ado + Hcy (50 or 200 mg/kg of 
each) 40 min prior to death. [3H]Histamine (1 pCi/lO PI) was 
injected into the lateral cerebral ventricle 5 min prior to 
death. Results are expressed in d.p.m./g x ? S.E.M. in six 
to seven mice. Stars denote a significant difference from cor- 
responding vehicletreated controls at the 0.05 level, using 
Student's t-test (two-tailed). Total radioactivity ([d.p.m./g] x 
of control, Ado + Hcy (50 mglkg), and Ado + Hcy (200 
mglkg) groups was 5.67 2 0.53,4.83 -t 0.41. and 4.96 ? 0.42, 
respectively. There was no significant difference between 
either drug-treated group and the controls ( p  > 0.05). 
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TABLE 2. Eflect of Ado + Hcy on mouse brain histamine levels and 





Treatment" nglg _f S.E.M.  (N) % Change' p" nmoVg 5% Change 
Saline 69.9 2 9.6 (6) - - 7.3 - 
50 m&g 90.9 2 9.6 (6) + 30 NS 4.2 - 42 
200 mglkg 116.0 2 15.0 (6) +66 ~ 0 . 0 2  2.5 -66 
- 
" Mice were injected intraperitoneally with adenosine and D,L-homocysteine 
thiolactone (50 or 200 mglkg of each) or salinenween 80 (20 mYkg) 40 min before 
killing. 
Conversion index: (d.p.m./g brain [3H]methylhistamine)/(histamine specific 
activity in d.p.m.lnmo1). 
' % Change values compared with saline-treated mice. 
" P values were determined by Student's r-test (two-tailed); P values greater 
than 0.05 were considered not significant (NS). 
using an isotope dilution-ion exchange-HPLC assay 
system sensitive to less than 10 pmol. These levels 
are at the lower limit of the range of values reported 
in the literature, the only exception being the very 
low levels of AdoHcy in blood (0.15 nmollml; Fig. 
3). Our data confirm that tissue AdoMet levels are 
generally higher than those of AdoHcy (Eloranta, 
1977; Cantoni et al., 1979). 
Administration of Ado + Hcy was much more 
effective in elevating AdoHcy levels than was an 
equimolar dose of the intact molecule, AdoHcy 
(Table 11, indicating that AdoHcy can effectively be 
synthesized from Ado and Hcy in vivo by AdoHcy 
hydrolase. Others have suggested that the main 
biologic function of AdoHcy hydrolase is the hy- 
drolysis of AdoHcy, hence-indirectly-the regu- 
lation of transmethylation reactions (De la Haba 
and Cantoni, 1959; Deguchi and Barchas, 1971). It 
is known, however, that in vitro synthesis of 
AdoHcy is thermodynamically favored (Walker and 
Duerre, 1975; Schatz et al., 1979). 
The inability (compared with Ado + Hcy) of ex- 
ogenously administered AdoHcy to increase tissue 
AdoHcy levels suggests that cells are relatively im- 
permeable to AdoHcy (Miller and Duerre, 1969; 
Duerre et a]., 1969; Knudsen and Yall, 1972), but 
readily allow passage of Ado and Hcy individually 
(Walker and Duerre, 1975; Knudsen and Yall, 
1972). Another, and less likely, possibility is that 
AdoHcy is rapidly hydrolyzed in vivo; however, the 
intravenous administration of 13H]AdoHcy resulted 
in urinary excretion of essentially all of the radio- 
activity as unaltered AdoHcy (Walker and Duerre, 
1975). 
The dramatic increase in hepatic AdoHc y levels 
(Fig. 2) indicates that the liver possesses greater 
AdoHcy synthetic capability than blood or brain 
(Figs. 1 and 3), which is in agreement with previous 
observations that AdoHcy hydrolase activity is 
much higher in liver than in other tissues tested 
(Finkelstein and Harris, 1973; Walker and Duerre, 
1975; Eloranta, 1977; Schatz et al., 1977a). Addi- 
tionally, intraperitoneal injection favors the initial 
passage of a large portion of the drugs through the 
hepatic portal system (Lukas et al., 1971). The 
AdoHcy in blood may be due to the spillover of 
excess AdoHcy from other organs or from direct 
synthesis by blood AdoHcy hydrolase. The exis- 
tence of AdoHcy hydrolase in blood remains unre- 
ported; however, blood has been shown to contain 
AdoMet synthetase (EC 2.5.1.6) (Baldessarini, 
1975), as well as several methyltransferases (Axel- 
rod and Cohn, 1971; Kim, 1974; Prozialeck et al., 
1978; Cheng and Kazazian, 1978; Weinshilboum et 
al., 1979; Strittmatter et al., 1979). Interestingly, 
AdoMet synthetase and AdoHcy hydrolase gener- 
ally exhibit a parallel tissue distribution, AdoHcy 
hydrolase being more active than AdoMet syn- 
thetase (Baldessarini, 1975; Eloranta, 1977; Finkel- 
stein, 1979). 
The administration of Ado + Hcy markedly ele- 
vated AdoMet levels in blood and liver (Figs. 2 and 
3), while brain AdoMet appeared to be resistant 
(Fig. 1). The peripheral increase in AdoMet is pre- 
sumably due to inhibition of transmethylation 
caused by the high levels of AdoHcy, a finding that 
is in agreement with the observation of Chiang and 
Cantoni (1979), who showed that the in vivo eleva- 
tion of tissue AdoHcy after 3-deazaAdo resulted in 
increases of AdoMet and decreases in the methyla- 
tion of liver phospholipids and guanidoacetic acid 
and in the urinary excretion of VMA. Conversely, 
brain levels of AdoMet were unchanged after doses 
of Ado + Hcy as high as 500 mglkg (Fig. l), indi- 
cating that cerebral transmethylations may be more 
resistant to inhibition by AdoHcy. Despite that, 
HMT and COMT activities in brain were inhibited 
after 1 glkg of Ado + Hcy (Fig. 5).  Initial experi- 
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ments using lower doses of Ado + Hcy (200 mglkg) 
(data not shown) provided inconsistent results in 
terms of HMT or COMT inhibition. This is not par- 
ticularly surprising, in consideration of the fact that 
in vitro enzyme determinations disrupt cellular in- 
tegrity, thus potentially diluting the effects of en- 
zyme inhibitors administered in vivo. Further, the 
greatest observed increase in AdoHcy levels (in 
liver after 1 g/kg Ado + Hcy), extrapolates to a 
concentration of about 1.5 p ~ ,  assuming a 70% vol- 
ume of distribution (Cizek, 1954), a concentration 
which is at the lower end of the range of Ki values 
determined for AdoHcy toward various methyl- 
transferases in vitro (Cantoni et al., 1979). 
Dialysis of brain and liver homogenates from 
Ado + Hcy-treated mice effectively alleviated the 
inhibition of HMT (Fig. 6), further indicating that its 
inhibition was due to the presence of high endoge- 
nous concentrations of AdoHcy. Since an accurate 
determination of the activity of AdoHcy hydrolase 
using our HPLC assay system was confounded by 
the high tissue levels of AdoHcy after Ado + Hcy, 
the tissue preparations were dialyzed prior to the 
assay. The finding that AdoHcy hydrolase activity 
remained significantly decreased after dialysis (Fig. 
7) is therefore of particular interest. Additionally, 
this inhibition was evident at a much lower dose of 
administered Ado + Hcy than that required to in- 
hibit COMT or HMT. Since the kinetics of AdoHcy 
hydrolase are complex and, at present, poorly un- 
derstood, the reason for the persistent inhibition of 
AdoHcy hydrolase is unclear. Recent evidence 
(Hershfield and Kredich, 1978; Ueland and Saebo, 
1979) indicates that AdoHcy hydrolase binds 
adenosine tightly, and perhaps the inhibition of the 
cerebral enzyme in dialyzed homogenates from 
Ado + Hcy-treated mice is the result of such binding. 
The maximal, and short-lived, elevation of brain 
AdoHcy levels after 200 mglkg of Ado + Hcy was 
at 40 min, with no concurrent alterations of brain 
AdoMet (Fig. 4). To produce an elevation of liver 
AdoHcy levels, minimally two injections of 3- 
deazaAdo (100 mg/kg) were required (Chiang and 
Cantoni, 1979). These findings indicate that the 
body is capable of rapidly and effectively coping 
with increased tissue levels of AdoHcy. Indeed, as 
the enzymes of transsulfuration (Finkelstein, 1979) 
and the adenosine deamination pathways (Cortese 
et al., 1974; Hoffman et al., 1979; Schatz et al., 
1977~) are even more active than AdoHcy hydro- 
lase (Eloranta, 1977), there exists an overall homeo- 
static capacity to counteract long-lasting changes in 
AdoHcy levels. 
The dose-related decreases in [3H]HA methyla- 
tion in mouse brain after Ado + Hcy (Fig. 8) are in 
agreement with similar observations of Chiang and 
Cantoni (1979), who noted that the in vivo methyla- 
tion of hepatic catechols, guanidoacetic acid, and 
phospholipids decreased after elevation of liver 
AdoHcy levels. Although the inhibition of methyla- 
tion noted by Chiang and Cantoni (1979) was un- 
doubtedly, at least in part, due to elevated tissue 
AdoHcy, other factors may confound the interpre- 
tation of the results of experiments in which 
deazaAdo was administered: (1) deazaAdo is a sub- 
strate as well as an inhibitor of AdoHcy hydrolase 
(Chiang et al., 1977; Cantoni et al., 1979); (2) 3- 
deazaAdoHcy formed from deazaAdo inhibits 
methyltransferases (Borchardt, 1975; Leboy et al., 
1978; Cantoni et al., 1979); and (3) some methyla- 
tion reactions are inhibited in vivo by elevated 
AdoMet levels alone (Reilly and Schayer, 1978; 
Schatz et al., 1981). 
In addition to inhibiting the catabolism of exoge- 
nous [3H]HA, the administration of Ado + Hcy led 
to a dose-related increase in endogenous HA levels 
and a decrease in the transmethylation conversion 
index, which is an estimate of the transmethylation 
“flux” (Table 2) (Schatz et al., 1978; 1981). Addi- 
tionally, as work in progress has revealed, cerebral 
protein carboxymethylation and phospholipid 
methylation are also inhibited after Ado + Hcy 
(data not shown). 
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